bottom line overweight rate reflect
view
sustain follow
acquisit close end solid
result continu execut initi despit intern
extern nois support thesi
sale acceler
life scienc profil overshadow quarter
start shine cytiva mix report core
growth pro-forma basi includ cytiva
compar forecast better expect growth
diagnost ea drove upsid segment
ahead expect diagnost standout quarter
like near term due covid test relat tailwind
nice increment growth opportun believ
cytiva ge biopharma integr continu high qualiti life
scienc platform compani assembl start materi
acceler growth profil
simultan cytiva integr ceo transit strateg
covid project highlight strength db
compani report result surpris announc
ceo tom joyc step elev head life
scienc replac manag note success
plan work year believ
compani abil manag major acquisit integr launch
improv via danah busi system db deal
covid macro headwind major manag
transit highlight strength compani long term
strategi mr joyc stay next year ensur smooth
transit believ much extern intern nois
two concurr ceo support stanc compani emerg
major mileston attract long term
compani data secur llc estim reuter
non-gaap ep exclud amort acquisition-rel intang asset
exclud cost incur pursuant discret restructur plan
non-gaap ep exclud amort acquisition-rel intang asset
one time cost
compani data secur llc estim reuter
updat estim reflect go forward pro-forma report
macro covid headwind diagnost tailwind
bake potenti increment upsid opportun
updat forecast loop cytiva pro-forma forecast
harsher expect near term headwind core busi
partial off-set covid relat tailwind mid long term
core busi forecast improv stronger bioprocess outlook
includ potenti benefit new covid serolog
product launch could provid upsid estim
increas target price base
ev/ebitda multipl forecast
ep previous
pro-forma ebitda estim improv
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
price target
price target reflect enterpris valu use project level debt cash includ
assumpt around ge biopharma contribut pro-forma ebitda ex
option multipl premium life scienc tool diagnost high qualiti
industri peer group believ appropri given prospect faster earn growth
downsid risk overweight rate includ limit follow factor first given
scale recent deal flow acquisit target select integr risk stand potenti
headwind investor interest stori second signific global exposur lead risk
neg impact global macro deterior gener well china headwind specif
final competit pressur especi diagnost could weigh futur profit
overweight rate reflect view sale acceler sustain follow
propos acquisit close end
washington dc-base corp nyse industri conglomer focus use
continu improv techniqu improv perform acquir busi compani
product typic distinguish strong brand name innov technolog major market
posit razor/razor-blad busi model compani oper four segment life scienc
diagnost dental environment appli life scienc segment sell mass spec
chromatographi filtrat microscopi centrifug flow cytometri product pharma academia
certain industri end market diagnost sell wide varieti diagnost test equip
hospit lab refer lab patholog lab point-of-car set dental sell orthodont
implant dispos tool larger equip dental offic environment appli divid
two piec water qualiti product identif
